University of Cambridge spin-out converting adherent cells into barcoded, assay-ready microcarriers (SemaCyte) for drug discovery.
| Date | Round | Amount |
|---|---|---|
| Mar 2026 | Seed Cambridge's Semarion raised GBP 2.9M led by Parkwalk to scale its SemaCyte cell-assay platform for drug discovery. | $3.7M |
Tap an investor to see what else they have backed.
Data is community-curated and may be incomplete.